Summary in a Minute
Peptide Receptor Radionuclide Therapy (PRRT) is a targeted treatment for neuroendocrine tumors (NETs) in India that utilizes a radioactive peptide to selectively bind to cancer cells expressing specific receptors. This therapy minimizes damage to surrounding healthy tissues while delivering localized radiation to destroy tumor cells. PRRT Therapy in India offers significant benefits, including improved quality of life through symptom relief and the potential for tumor stabilization or shrinkage, particularly for patients with advanced tumors not amenable to surgery or conventional therapies.
Overview
Peptide Receptor Radionuclide Therapy (PRRT) is a targeted treatment for neuroendocrine tumors (NETs). It uses radiolabeled peptides that bind to specific receptors on tumor cells, delivering targeted radiation to destroy cancerous tissue. PRRT is most effective for tumors expressing somatostatin receptors, such as those found in the pancreas and intestines. It offers a non-invasive, effective treatment option for advanced or metastatic NETs, especially when other therapies have failed, improving survival and quality of life.
Mechanism of Action
1. Lu-177 is attached to a peptide that binds to somatostatin receptors.
2. The complex targets and binds to NET cells.
3. Beta radiation emitted by Lu-177 kills cancer cells.
Indications
1. Advanced NETs (e.g., pancreatic, small cell lung cancer).
2. Gastroenteropancreatic NETs (GEP-NETs).
3. Somatostatin receptor-positive tumors.
Contra-Indications
1. Pregnancy or breastfeeding.
2. Severe kidney impairment.
3. Known hypersensitivity to Lu-177 or somatostatin analogs.
Dosage and Administration
1. Typical dose: 7.4 GBq (200 mCi) per cycle.
2. Administration: Intravenous injection, usually every 8 weeks.
3. Number of cycles: 4-8.
Efficacy
1. Improved progression-free survival: PRRT significantly extends time without tumor progression, offering better long-term outcomes for patients.
2. Reduced tumor burden: PRRT Therapy in Delhi NCR effectively shrinks tumors, reducing size and number of lesions in neuroendocrine tumors.
3. Enhanced quality of life: Patients experience fewer symptoms, improved energy levels, and reduced pain, leading to better overall well-being.
Side Effects
1. Nausea and vomiting.
2. Fatigue.
3. Bone marrow suppression (Rare).
4. Kidney damage (Rare).
Radiation Safety
1. Standard radiation safety protocols.
2. Patient isolation (24-48 hours).
Combination Therapies
1. Chemotherapy.
2. Somatostatin analogs (Sandostatin).
3. Immunotherapy.
Clinical Trials
1. NETTER-1 trial (NCT01523616).
2. COMPETE trial (NCT00978112).
3. FDA-approved (January 2018).
4. EMA-approved (September 2017).
FAQs about PRRT Therapy
PRRT is primarily used for neuroendocrine tumors (NETs) that express somatostatin receptors. This includes tumors originating in the pancreas, gastrointestinal tract, and lungs. It is particularly beneficial for patients with advanced or metastatic NETs that cannot be surgically removed.
A typical PRRT session lasts several hours, during which the radiolabeled peptide is administered intravenously. Patients usually undergo multiple cycles of treatment, spaced several weeks apart, depending on their individual response and treatment plan.
Before PRRT, patients typically undergo imaging studies to assess receptor expression and overall health. It’s important to inform the healthcare team about any medications, allergies, or existing health conditions. Patients may also receive hydration and anti-nausea medications to enhance comfort during treatment.
Common side effects of PRRT include nausea, fatigue, and temporary changes in blood cell counts. Most side effects are manageable and resolve over time. Patients are closely monitored during and after treatment to address any concerns and ensure safety.
Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.
Contact Information
Contact for appointments for Scans and Therapies.
Phone
+91-9650057298
+91-9355258181
Address
Sector 8, Faridabad, Haryana, India
